SynthesisJournal of robotic surgery2026
Transoral robotic surgery for glottic squamous cell carcinoma: a systematic review and patient-level analysis of surgical, functional, and oncologic outcomes.
Synthesis in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Audiometric Monitoring and Its Determinants in Patients Undergoing Chemoradiotherapy for Head and Neck Cancer.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence regarding the role of transoral robotic surgery (TORS) in glottic squamous cell carcinoma (GLSCC) remains limited. This systematic review aimed to evaluate the surgical, functional, and oncologic outcomes of TORS for GLSCC through a patient-level analysis. A PRISMA-compliant systematic review was conducted using PubMed, Scopus, and the Cochrane Library through 31 May 2026. Surgical, functional, and oncologic outcomes were extracted, and Kaplan-Meier analyses were performed when patient-level follow-up data were available. Fifteen studies including 134 patients were analyzed, comprising 91 robotic cordectomies, 21 robotic partial laryngectomies, and 22 robotic total laryngectomies. Robotic cordectomy was associated with short operative times (20.0 ± 10.8 min), minimal blood loss (13.2 ± 9.0 mL), and a low conversion rate (2.2%). Temporary tracheostomy, and feeding tube dependence occurred in 4.4%, and 12.4%, respectively. Robotic partial laryngectomy demonstrated favorable functional outcomes, with successful decannulation and feeding tube removal reported in all available cases. Five-year local control, disease-specific survival, and overall survival following robotic cordectomy were 86.5%, 97.5%, and 93.6%, respectively. In the robotic total laryngectomy cohort, 5-year local, regional, and distant disease control rates exceeded 90%, although oncologic outcomes for robotic partial laryngectomy could not be reliably assessed because of insufficient follow-up data. TORS appears to be a feasible treatment option for selected patients with GLSCC, providing encouraging surgical, functional, and oncologic outcomes. However, the available evidence remains limited to small retrospective studies, and larger comparative investigations are needed to better define its role in clinical practice.
Indexed as
Identifiers
42584545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.